Connect with us

BioPharma

Cyberlux Corporation (OTC: CYBL) Strong Move Northbound as (DoD) Contractor Establishes Drone Business Unit FlightEye Drone Solutions & Forms Partnership with Strike Group, LLC

Published

on

Cyberlux Corporation (OTC: CYBL) has made a powerful run up the charts in recent weeks since we first reported on it in July when it was under a penny to recent highs of $0.066. The stock has established itself as among the top most traded stocks in small caps with daily dollar volume regularly in the $10 to $20 million dollar range.  CYBL has emerged as an investor favorite and is among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation CYBL is looking to blaze a path along the likes of Tesoro or Enzolytics – Tesoro went to multi dollars – CYBL is looking for a break over $0.066 and another blue-sky breakout. 

It’s easy to get excited about CYBL; an active Department of Defense (DoD) contractor providing leading-edge, battle-tested lighting solutions to the U.S. Air Force, National Guard, Special Operations Command (SOCOM), and the U.S. Army. Management has been hard at work getting their filings in order and recently went to “pink current” on OTCMarkets. Management has been working with the share structure and enacting a no reverse split policy as they move the AS from 20 billion down to 8.75 billion. The Company established its drone business unit, FlightEye Drone Solutions with the acquisition of CTMC Drone Solutions, LLC and formed a Channel Delivery Partnership with Strike Group, LLC a world leader in sustainment logistics, infrastructure delivery, and material sourcing for U.S. Agencies, the Department of Defense, and the commercial contracting marketplace, to drive the adoption, contracting and revenue of the FlightEye Drone Solutions products and the Cyberlux Infrastructure products including LED street lighting and solar power solutions. Microcapdaily first reported on CYBL on July 11 when the stock was trading for well under a penny. 

Corporation (OTC: CYBL) operating out of Research Triangle Park, North Carolina is a leader in solid-state lighting innovation tht has developed breakthrough LED lighting and energy efficiency technology, with solutions available today in U.S. government agencies, commercial markets and international opportunities. The Company provides unique solutions to the Department of Defense (DoD), Commercial channels and Design Services customers. Since 2006, Cyberlux has provided leading-edge, battle-tested lighting solutions to the U.S. Air Force, National Guard, Special Operations Command (SOCOM), and the U.S. Army.  As the Company’s primary channel, Cyberlux supplies the DoD with light-weight, portable battery-powered advanced LED lighting systems for special operators, forward-base operations, security and maintenance lighting. After early consumer product trials, the Company has focused on DoD lighting technology and serving the Military, First Responder and related Commercial markets, primarily with the BrightEye Tactical Lighting System products. The Company’s mission is to be the trusted provider of advanced lighting solutions to Commercial, Government and Military organizations worldwide. The Company had a governent contract in Durham, North Carolina that ended on March 31, 2021. CYBL owns a suite of patented products that can be seen here. 

On July 18 CYBL released its second quarter of 2021 results which showed a significant increase in revenue year-to-year and demonstrated that the Company is accomplishing its growth milestones as it continues to recover from the impact of the COVID shutdown during 2020. The Company is now accelerating its growth through existing business channels, access to new markets, and through a Company-wide focus on acquisitions and joint ventures. CYBL has now posted all amended filings to OTC Markets and sees OTC Current status as imminent. 

Revenues for the three months ended June 30, 2021 were $367,231 as compared to $ -0- for the same period last year due to the impact of the COVID shutdown. The Company recorded an income from operations of $591,868 for the six months ended June 30, 2021. Operating expenses for the three months ended June 30, 2021 were ($153,681) as compared to $17,887 for the same period ended June 30, 2020. Included in the three months ended June 30, 2021 were the write-off of old liabilities in the amount of $231,625. 

https://twitter.com/Shellhead_1/status/1442238072326959104

To Find out the inside Scoop on CYBL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CYBL

In August the Company moved into the drone space with the acquisition of CTMC Drone Solutions, LLC to the Cyberlux business as its drone capability platform, including key technology assets and personnel resources, creating the foundation for the new Cyberlux drone business unit, FlightEye Drone Solutions. The new business unit, wholly-owned by Cyberlux Corporation, will focus on unmanned aircraft systems (UAS) including drone-related technology and intellectual property development, manufacturing, drone services, and government and commercial sales. Through this drone technology platform, Cyberlux Corporation intends to build the technology and production capability to create ongoing growth in revenue, profit, and shareholder value. Cyberlux anticipates making future cash investments for ongoing product development and working capital for business expansion. The specific terms of the deal are limited in disclosure until Cyberlux Corporation is fully Pink Current Information on the OTC Markets. 

Going forward, FlightEye Drone Solutions will leverage its core technology capability to provide compact, next-generation military-grade UAS products and drone solution packages built around proprietary Cyberlux LED lighting, infrared night vision capability, thermal sensor technology, eye-in-the-sky monitoring capabilities, and LiDAR mapping and perception technologies. The business unit is immediately focused on existing Department of Defense (DoD) requirements and existing Broad Area Announcement (BAA) research and development opportunities, including geofencing capabilities, observe and monitor alert systems, collision avoidance capabilities, beyond-line-of-sight operations, urban area operations, operating system support for multiple drone operation and traffic management, and other critical priorities such as weight optimization and energy efficiency. 

Defense, Space and Technology Industry expert Larson J. Isely is leading the Companys FlightEye Drone Solutions Division as Cyberlux Executive Vice President and General Manager of the Unmanned Aircraft Systems (UAS) business unit. Mr. Isely, one of the core technical contributors to the Cyberlux illumination patents and technology platform that underpins the Companys Department of Defense (DoD) products, is joining Cyberlux Corporation after 11 years as a technical executive and data scientist in the Technology and Financial industries.  

On September 24 CYBL announced the Company has formed a Channel Delivery Partnership with Strike Group, LLC to drive the adoption, contracting and revenue of the FlightEye Drone Solutions products and the Cyberlux Infrastructure products including LED street lighting and solar power solutions. Strike Group, LLC, is a world leader in sustainment logistics, infrastructure delivery, and material sourcing for U.S. Agencies, the Department of Defense, and the commercial contracting marketplace, with expertise in distribution, logistics and infrastructure delivery. Since 1998, Strike Group has been an L-3 Integrated Systems Group partner and has helped deliver aircraft modernization and mission systems integration to mission-critical locations around the world.  

Under the terms of the Agreement, Strike Group, LLC will provide marketing, sales, contracting and delivery support for the Cyberlux FlightEye Drone Solutions products and Infrastructure products, including both tactical and strategic contracting, access to senior government decision-makers in the emerging UAS (unmanned aircraft systems) marketplace, and access to specific U.S. agency requirements for ongoing Cyberlux technology and solution development. Strike Group will provide solution sales support for all U.S. governmental agencies, including expansion into new agencies currently not served by Cyberlux products.  

Cyberlux CEO Mark Schmidt commented: “We have been working with Lane and the Strike Group team to launch this exciting channel delivery partnership, and we are so excited by their DoD reach, their market understanding and their delivery capabilities. For our launch of the FlightEye Drone Solutions products, the Strike Group team has vast experience in the aviation market that sets up perfectly for Cyberlux to gain UAS leadership. From an infrastructure standpoint, Strike Group has ongoing projects federal, state and local where Cyberlux products are a perfect fit. With this Strike Group channel delivery relationship, we now have the incremental capability to truly drive market leadership in the UAS and Infrastructure vertical markets. We are now positioned to take full advantage of the coming infrastructure spending as well, said Mr. Schmidt. 

 For More on CYBL Subscribe Right Now!

CYBL has made a powerful run up the charts in recent weeks since we first reported on it in July when it was under a penny to recent highs of $0.066. The stock has established itself as among the top most traded stocks in small caps with daily dollar volume regularly in the $10 to $20 million dollar range.  CYBL has emerged as an investor favorite and is among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation CYBL is looking to blaze a path along the likes of Tesoro or Enzolytics – Tesoro went to multi dollars – CYBL is looking for a break over $0.066 and another blue-sky breakout. It’s easy to get excited about CYBL; an active Department of Defense (DoD) contractor providing leading-edge, battle-tested lighting solutions to the U.S. Air Force, National Guard, Special Operations Command (SOCOM), and the U.S. Army. Management has been hard at work getting their filings in order and recently went to “pink current” on OTCMarkets. Management has been working with the share structure and enacting a no reverse split policy as they move the AS from 20 billion down to 8.75 billion. The Company established its drone business unit, FlightEye Drone Solutions with the acquisition of CTMC Drone Solutions, LLC and formed a Channel Delivery Partnership with Strike Group, LLC a world leader in sustainment logistics, infrastructure delivery, and material sourcing for U.S. Agencies, the Department of Defense, and the commercial contracting marketplace, to drive the adoption, contracting and revenue of the FlightEye Drone Solutions products and the Cyberlux Infrastructure products including LED street lighting and solar power solutions. Microcapdaily first reported on CYBL on July 11 when the stock was trading for well under a penny. We will be updating on CYBL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYBL.

Disclosure: we hold no position in CYBL either long or short and we have not been compensated for this article.

 

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.